Nisa Investment Advisors LLC Acquires 4,332 Shares of McKesson Corporation $MCK

Nisa Investment Advisors LLC grew its holdings in shares of McKesson Corporation (NYSE:MCK) by 9.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 48,209 shares of the company’s stock after acquiring an additional 4,332 shares during the quarter. Nisa Investment Advisors LLC’s holdings in McKesson were worth $39,584,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in MCK. Alliancebernstein L.P. increased its holdings in shares of McKesson by 150.4% during the second quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock worth $1,661,956,000 after buying an additional 1,362,386 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of McKesson by 56.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock valued at $906,109,000 after acquiring an additional 446,060 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in McKesson by 45.6% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 833,780 shares of the company’s stock worth $610,977,000 after acquiring an additional 261,296 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in McKesson by 34.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 839,690 shares of the company’s stock worth $615,305,000 after purchasing an additional 213,406 shares in the last quarter. Finally, SurgoCap Partners LP increased its holdings in McKesson by 68.7% in the 3rd quarter. SurgoCap Partners LP now owns 452,261 shares of the company’s stock worth $349,390,000 after purchasing an additional 184,106 shares in the last quarter. Institutional investors own 85.07% of the company’s stock.

McKesson Price Performance

MCK stock opened at $864.99 on Wednesday. The company’s 50-day moving average is $908.89 and its 200-day moving average is $842.77. The stock has a market capitalization of $105.95 billion, a PE ratio of 24.88, a price-to-earnings-growth ratio of 1.38 and a beta of 0.38. McKesson Corporation has a 1 year low of $637.00 and a 1 year high of $999.00.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The business had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the prior year, the business earned $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, analysts anticipate that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s dividend payout ratio is presently 9.43%.

Insider Buying and Selling

In related news, EVP Michele Lau sold 2,725 shares of McKesson stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total value of $2,697,750.00. Following the completion of the sale, the executive vice president owned 3,247 shares of the company’s stock, valued at approximately $3,214,530. This trade represents a 45.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $955.00, for a total transaction of $313,240.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,868 shares of company stock worth $3,743,820 over the last quarter. Corporate insiders own 0.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on MCK shares. Evercore reissued an “outperform” rating on shares of McKesson in a research note on Thursday, March 5th. TD Cowen upped their price objective on McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a research note on Thursday, February 5th. JPMorgan Chase & Co. raised their price objective on shares of McKesson from $983.00 to $1,107.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Wall Street Zen upgraded shares of McKesson from a “hold” rating to a “buy” rating in a research report on Sunday, March 22nd. Finally, Mizuho boosted their target price on shares of McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a report on Thursday, February 5th. Thirteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, McKesson presently has an average rating of “Moderate Buy” and a consensus target price of $960.93.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.